Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial | Zendy

Thomas J. Walsh | Zendy; Issam Raad | Zendy; Thomas F. Patterson | Zendy; Pranatharthi Chandrasekar | Zendy; Gerald R. Donowitz | Zendy; Richard Graybill | Zendy; Reginald E. Greene | Zendy; Ray Hachem | Zendy; Susan Hadley | Zendy; Raoul Herbrecht | Zendy; Amelia Langston | Zendy; Arnold Louie | Zendy; Patricia Ribaud | Zendy; Brahm H. Segal | Zendy; David A. Stevens | Zendy; JoAnne H. van Burik | Zendy; Charles S. White | Zendy; Gavin Corcoran | Zendy; Jagadish Gogate | Zendy; Gopal Krishna | Zendy; Lisa D. Pedicone | Zendy; C. Hardalo | Zendy; John R. Perfect | Zendy

Open Access

Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial

Author(s) -

Thomas J. Walsh,

Issam Raad,

Thomas F. Patterson,

Pranatharthi Chandrasekar,

Gerald R. Donowitz,

Richard Graybill,

Reginald E. Greene,

Ray Hachem,

Susan Hadley,

Raoul Herbrecht,

Amelia Langston,

Arnold Louie,

Patricia Ribaud,

Brahm H. Segal,

David A. Stevens,

JoAnne H. van Burik,

Charles S. White,

Gavin Corcoran,

Jagadish Gogate,

Gopal Krishna,

Lisa D. Pedicone,

C. Hardalo,

John R. Perfect

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/508774

Subject(s) - posaconazole , medicine , aspergillosis , neutropenia , refractory (planetary science) , voriconazole , salvage therapy , population , transplantation , hematopoietic stem cell transplantation , surgery , gastroenterology , immunology , chemotherapy , antifungal , dermatology , biology , astrobiology , environmental health

Invasive aspergillosis is an important cause of morbidity and mortality in immunocompromised patients. Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research